Figure 2.

Association of anti-SARS-CoV-2 spike IgG with vaccine types and cancer types

(A) Patients with hematologic malignancies had lowest titers when compared with those with solid tumors and non-cancer patient controls. No difference was seen between patients with solid tumors and controls.

(B) Anti-spike protein IgG antibody titers (AU/mL) were significantly higher in patients who received mRNA vaccines than in those who received adenoviral vaccine.

Box plots here and in subsequent figures show median (horizontal bar), the 75^th and 25^th quartiles, and error bars depicting the largest and smallest values (up to 1.5 times the interquartile range). Differences assessed by Kruskal-Wallis test.